Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | UQCRB | P14927 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11848869 | 0.86 | HTR6 (0.44) | ALDH1A1KMT2ALMNACA12CA1 | |
| SCHEMBL12373175 | 0.83 | NPY2R (0.50) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL23555108 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KMT2ALMNACA12CA1 | |
| SCHEMBL13101211 | 0.77 | TDP1 (0.46) | ALDH1A1KMT2ALMNACA12CA1 | |
| SCHEMBL2646217 | 0.76 | ENPP2 (0.56) | ESR1ENPP2ALDH1A1ESR2KMT2A | |
| SCHEMBL6510279 | 0.74 | KEAP1 (0.44) | ALDH1A1KMT2ALMNACA12CA1 | |
| SCHEMBL29017574 | 0.74 | LTA4H (0.41) | ESR1ALDH1A1ESR2KMT2ALMNA | |
| SCHEMBL3751598 | 0.74 | ALDH1A1 (0.68) | ALDH1A1KMT2AADAMTS4 | |
| SCHEMBL3757552 | 0.74 | ALDH1A1 (0.68) | ALDH1A1KMT2AADAMTS4 | |
| SCHEMBL312933 | 0.74 | LCK (0.47) | ALDH1A1KMT2ALMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | disclosed |
| CN-101917845-A | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD | 2010-12-15 | — | — | CN | disclosed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | VAPA, SLC6A11, VAPB | ESR1 4745/4885ENPP2 1553/4885ALDH1A1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.